Gilead Sciences, Inc. (GILD)
GILDNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$167.58
-0.5000 (-0.30%) today
Closed, Nov 16, 4:00 PM ET
- Market cap
- $208.48bn
- P/E
- –
- EPS, last 4 quarters
- $-0.3100
- Dividend yield
- 1.95%
- Day range
- –
- 52-week range
- $116.88 to $176.58
- Average volume
- –
- Previous close
- $168.08
Analysts
22 coveringBuy17 buy, 5 hold, 0 sell
Targets a year out average $174.48, +4.1% from here
Earnings
next estimate $1.14Next report
Dec 2025
+1.6%
Mar 2026
+7.4%
Jun 2026
+4.5%
Sep 2026
+17.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $7.92bn | $6.96bn | $7.80bn | $8.30bn |
| Gross profit | $6.30bn | $5.51bn | $6.22bn | $6.73bn |
| Operating income | $1.98bn | $2.59bn | -$10.39bn | $3.46bn |
| Net income | $2.18bn | $2.02bn | -$10.50bn | $2.43bn |
Last four quarters: revenue $30.99bn, margin -12.5%, free cash flow $13.78bn
News
8 latest- Gilead Broadens Ebola Strategy With Obeldesivir Licensing Deals, Remdesivir Agreement Expansion RTTNews · 1 hour ago
- These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys The Motley Fool · 7 hours ago
- DGRW, GILD, TMUS, IBM: ETF Inflow AlertBNK Invest · 14 hours ago
- The Zacks Analyst Blog Highlights Home Depot, Gilead Sciences, TotalEnergies, Key Tronic and iPowerZacks · 4 days ago
- Top Research Reports for Home Depot, Gilead & TotalEnergiesZacks · 4 days ago
- 3 Pharmaceutical Stocks That Offer Safety and GrowthMarketBeat · 5 days ago
- Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?Zacks · 5 days ago
- ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?Zacks · 6 days ago
The company
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness, while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- gilead.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.